H1B Report
Side-by-side comparison

Sunrise Pharmaceutical Inc. vs TATA CONSULTANCY SERVICES LIMITED

A direct H-1B sponsorship comparison built from the same DOL Labor Condition Application data that drives every page on H1B Report. Total filings, outcome rates, top occupations and yearly demand side-by-side.

Entity A
Sunrise Pharmaceutical Inc.
NJRank #FEIN 20-1492434
Entity B
TATA CONSULTANCY SERVICES LIMITED
MDRank #3FEIN 98-0429806

Key metrics

All percentages are share of total LCAs filed by each sponsor.

MetricSunrise Pharmaceutical Inc.TATA CONSULTANCY SERVICES LIMITED
Total filings39128,379
Certified %97.44%99.22%
Denied %2.56%0.15%
Withdrawn %0.00%0.50%
Cert-withdrawn %0.00%0.13%
Rank#3
Active yearsFY2011–FY2025FY2010–FY2026
Worksite stateNJMD

Outcomes — Sunrise Pharmaceutical Inc.

DOL case-status mix.

Outcome breakdown: Certified 97.4%, Denied 2.6%
Outcome breakdown
OutcomeShare
Certified97.4%
Denied2.6%
Certified97.4%
Denied2.6%

Outcomes — TATA CONSULTANCY SERVICES LIMITED

DOL case-status mix.

Outcome breakdown: Certified 99.2%, Cert-withdrawn 0.1%, Withdrawn 0.5%, Denied 0.1%
Outcome breakdown
OutcomeShare
Certified99.2%
Cert-withdrawn0.1%
Withdrawn0.5%
Denied0.1%
Certified99.2%
Cert-withdrawn0.1%
Withdrawn0.5%
Denied0.1%

Yearly filing volume

Year-over-year H-1B demand for each sponsor.

Sunrise Pharmaceutical Inc.
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY20100
FY20115
FY20123
FY20135
FY20146
FY20153
FY20164
FY20172
FY20183
FY20193
FY20200
FY20210
FY20220
FY20230
FY20242
FY20253
FY20260
TATA CONSULTANCY SERVICES LIMITED
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY20101,008
FY20115,386
FY20126,700
FY20138,724
FY201413,977
FY201516,514
FY201613,100
FY201713,511
FY201814,583
FY201911,853
FY202023
FY202115
FY202211
FY20232,459
FY20249,708
FY20257,886
FY20262,921

Top 5 occupations — Sunrise Pharmaceutical Inc.

Top 5 occupations — TATA CONSULTANCY SERVICES LIMITED

Swap an entity
Replace either sponsor above without losing the comparison. 2-way for now; 3+ comparison coming soon.